Sanofi and GlaxoSmithKline (GSK) have announced that they have agreed to supply 60 million potential Covid-19 vaccines to the United Kingdom. While the news of potential COVID-19 vaccines prevails, yet there are no approved vaccines for the treatment of Covid-19.
This vaccine is expected to have its first clinical trials in September. GSK’s pandemic adjuvant technology and Sanofi’s S-protein Covid-19 antigens will be combined for the development of this vaccine.
The adjuvant used in these vaccines is claimed to be efficient energy boosters and has been used in many other vaccines. The adjuvant is added to the vaccines as they increase the immune response. Also, they are proven to create robust and prolonged immunity against any infections.
Any of the parties have disclosed no financial numbers. While GSK and Sanofi, who teamed up in April, have stated that a regulatory has approved the vaccine. This vaccine can be launched by the first half of 2021 if the clinical trials are positive.
President of GSK, Roger Connor said that the vaccine has the potential to play an important role in the eradication of the Covid-19 pandemic around the world. He also thanked the UK government for confirming the purchase of the vaccine, adding to the support of the efforts the company is making to speed up the development and production of the vaccine.
While a clinical development and registration of Covid-19 vaccine that is led by Sanofi are expecting the phase 1 and two of the clinical trial of the vaccine to start in September which will be followed by a phase 3 study by the end of 2020.
Along with this, Sanofi and GSK, are planning to accelerate the production of the antigen and adjuvant, to produce about 1 billion doses per year.
With this agreement, yet another vaccine can be added to the three other vaccines that are secured by the Vaccine Taskforce, said Kate Bingham ( UK Government Vaccine Taskforce).
He further added that the diversity in vaccines is needed, as we don’t know which of these will be able to generate an immunity towards Covid-19. The fact is we might never devise a vaccine and even if we do, the vaccine may not be able to prevent our bodies from contracting the virus, but turning out into the one that reduces the symptoms of it.
Sanofi and GSK are discussing supplying these vaccines to other countries that include France, Italy, and the European Union. They are hoping to provide 300 million doses of this vaccine to the European Union.
Two sources have claimed that the deal was blocked because GSK and Sanofi wanted a secure payment for the entire stock while the EU wants to delay the payments until the vaccines pass clinical trials.
Countries have devoted themselves to helping in whatever manner they can in the development of the virus.
They want to catalyze the process of vaccine- making, which usually takes a decade into a period of 12 to 18 months. Though the experts are worried that this might lead to the rich countries hoarding treatments while the poorer ones will have to wait.